TG Therapeutics (NASDAQ:TGTX) Now Covered by Analysts at TD Cowen

TD Cowen initiated coverage on shares of TG Therapeutics (NASDAQ:TGTX) in a report issued on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $50.00 price target on the biopharmaceutical company’s stock.

TGTX has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a report on Wednesday, September 18th. B. Riley boosted their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $36.33.

TG Therapeutics Trading Up 7.3 %

NASDAQ:TGTX opened at $26.90 on Tuesday. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $4.16 billion, a PE ratio of 44.10 and a beta of 2.21. The firm’s 50 day moving average is $23.51 and its 200 day moving average is $20.01. TG Therapeutics has a 12 month low of $9.81 and a 12 month high of $26.99.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The company had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $65.92 million. During the same quarter in the previous year, the firm posted ($0.34) EPS. TG Therapeutics’s revenue was up 357.0% on a year-over-year basis. Sell-side analysts expect that TG Therapeutics will post 0.12 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. NBC Securities Inc. grew its position in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares in the last quarter. Blue Trust Inc. grew its position in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in TG Therapeutics in the second quarter worth $35,000. ORG Wealth Partners LLC purchased a new position in TG Therapeutics in the third quarter worth $53,000. Finally, Values First Advisors Inc. purchased a new position in TG Therapeutics in the third quarter worth $58,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.